Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2014

Global Markets Direct
April 30, 2014
61 Pages - GMD12057
$2,000.00

Summary

Global Markets Direct’s, ‘Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2014’, provides an overview of the Female Hypoactive Sexual Desire Disorder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Female Hypoactive Sexual Desire Disorder and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Female Hypoactive Sexual Desire Disorder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Female Hypoactive Sexual Desire Disorder pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Female Hypoactive Sexual Desire Disorder
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Female Hypoactive Sexual Desire Disorder Overview 6
Therapeutics Development 7
Pipeline Products for Female Hypoactive Sexual Desire Disorder - Overview 7
Pipeline Products for Female Hypoactive Sexual Desire Disorder - Comparative Analysis 8
Female Hypoactive Sexual Desire Disorder - Therapeutics under Development by Companies 9
Female Hypoactive Sexual Desire Disorder - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Female Hypoactive Sexual Desire Disorder - Products under Development by Companies 13
Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development 14
Apricus Biosciences, Inc. 14
Palatin Technologies, Inc. 15
ANI Pharmaceuticals, Inc. 16
Fabre-Kramer Pharmaceuticals, Inc. 17
Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
flibanserin - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
testosterone - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
alprostadil - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
TGFK-09SD-ER - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
bremelanotide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
(sildenafil + testosterone) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(bupropion + trazodone hydrochloride) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(buspirone hydrochloride + testosterone) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Female Hypoactive Sexual Desire Disorder - Recent Pipeline Updates 43
Female Hypoactive Sexual Desire Disorder - Dormant Projects 55
Female Hypoactive Sexual Desire Disorder - Product Development Milestones 56
Featured News & Press Releases 56
Jul 29, 2013: S1 Biopharma Doses First Patients in Phase 2a Clinical Trial of Lorexys in Premenopausal Women with HSDD 56
Sep 04, 2012: BioSante Pharma Announces Positive LibiGel Phase III Safety Data Review And Decision To Conclude Safety Study 57
Feb 20, 2012: S1 Pharma Submits IND Application For SIP-104 For Treatment Of Hypoactive Sexual Desire Disorder 58
Jan 31, 2012: BioSante Pharmaceuticals Provides Update On Clinical Development Of LibiGel 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 61
Disclaimer 61

List of Tables
Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2014 7
Number of Products under Development for Female Hypoactive Sexual Desire Disorder - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Products under Development by Companies, H1 2014 13
Female Hypoactive Sexual Desire Disorder - Pipeline by Apricus Biosciences, Inc., H1 2014 14
Female Hypoactive Sexual Desire Disorder - Pipeline by Palatin Technologies, Inc., H1 2014 15
Female Hypoactive Sexual Desire Disorder - Pipeline by ANI Pharmaceuticals, Inc., H1 2014 16
Female Hypoactive Sexual Desire Disorder - Pipeline by Fabre-Kramer Pharmaceuticals, Inc., H1 2014 17
Assessment by Monotherapy Products, H1 2014 18
Assessment by Combination Products, H1 2014 19
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 25
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Female Hypoactive Sexual Desire Disorder Therapeutics - Recent Pipeline Updates, H1 2014 43
Female Hypoactive Sexual Desire Disorder - Dormant Projects, H1 2014 55

List of Figures
Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2014 7
Number of Products under Development for Female Hypoactive Sexual Desire Disorder - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 11
Assessment by Monotherapy Products, H1 2014 18
Number of Products by Top 10 Target, H1 2014 20
Number of Products by Stage and Top 10 Target, H1 2014 21
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29

$2,000.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax